Literature DB >> 16417574

Methamphetamine-induced spectrin proteolysis in the rat striatum.

Robert D Staszewski1, Bryan K Yamamoto.   

Abstract

Methamphetamine (METH) is a widely abused psychostimulant. Multiple high doses of METH cause long-term toxicity to dopamine (DA) and serotonin (5-HT) nerve terminals in the brain, as evidenced by decreases in DA and 5-HT content, decreases in tyrosine and tryptophan hydroxylase activities, decreases in DA and 5-HT re-uptake sites, and nerve terminal degeneration. Multiple high doses of METH are known to elicit a rapid increase in DA release and hyperthermia. Although METH also produces a delayed and sustained rise in glutamate, no studies have shown whether METH produces structural evidence of excitotoxicity in striatum, or identified the receptors that mediate this toxicity directly, independent of alterations in METH-induced hyperthermia. These experiments investigated whether METH can cause excitotoxicity as evidenced by cytoskeletal protein breakdown in a glutamate receptor-dependent manner. METH increased calpain-mediated spectrin proteolysis in the rat striatum 5 and 7 days after METH administration without affecting caspase 3-dependent spectrin breakdown. This effect was completely blocked with the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, GYKI 52466, but not the NMDA receptor antagonist, MK-801. However, AMPA or NMDA receptor antagonism did not attenuate the METH-induced depletions of the dopamine transporter (DAT). Independent mechanisms involved in mediating spectrin proteolysis and DAT protein loss are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417574     DOI: 10.1111/j.1471-4159.2005.03618.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  25 in total

1.  Methamphetamine-induced oxidation of proteins and alterations in protein processing.

Authors:  Bryan K Yamamoto; Fu-Chen Yang
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

Review 2.  Causes and consequences of methamphetamine and MDMA toxicity.

Authors:  Maria S Quinton; Bryan K Yamamoto
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

3.  N-Acetylcysteine amide protects against methamphetamine-induced oxidative stress and neurotoxicity in immortalized human brain endothelial cells.

Authors:  Xinsheng Zhang; Atrayee Banerjee; William A Banks; Nuran Ercal
Journal:  Brain Res       Date:  2009-04-15       Impact factor: 3.252

Review 4.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

5.  Chronic Methamphetamine Increases Alpha-Synuclein Protein Levels in the Striatum and Hippocampus but not in the Cortex of Juvenile Mice.

Authors:  B Butler; J Gamble-George; P Prins; A North; J T Clarke; H Khoshbouei
Journal:  J Addict Prev       Date:  2014

6.  Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function.

Authors:  Jamie Raudensky; Bryan K Yamamoto
Journal:  Brain Res       Date:  2007-01-02       Impact factor: 3.252

7.  Chronic stress enhances methamphetamine-induced extracellular glutamate and excitotoxicity in the rat striatum.

Authors:  Despina A Tata; Bryan K Yamamoto
Journal:  Synapse       Date:  2008-05       Impact factor: 2.562

8.  Peripheral ammonia and blood brain barrier structure and function after methamphetamine.

Authors:  Nicole A Northrop; Laura E Halpin; Bryan K Yamamoto
Journal:  Neuropharmacology       Date:  2016-03-10       Impact factor: 5.250

9.  Serial exposure to ethanol drinking and methamphetamine enhances glutamate excitotoxicity.

Authors:  Amanda L Blaker; Elizabeth R Moore; Bryan K Yamamoto
Journal:  J Neurochem       Date:  2019-10-15       Impact factor: 5.372

Review 10.  The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse.

Authors:  Bryan K Yamamoto; Jamie Raudensky
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.